drugset / Trial / NCT02485509

Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection

NCT02485509

Phase 1/2 Completed 28 enrolled Viriom
RandomizedParallel-groupDouble-blindTreatment

Summary

A combined Phase Ib and IIa randomized, placebo-controlled, double-blind study of VM-1500 in healthy subjects and in patients with HIV-1 infection that are antiretroviral therapy naïve.

Timeline

Start
2013-03
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Elsulfavirine Small molecule 20 mg
Subject Elsulfavirine Small molecule 40 mg